Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson's Disease

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2024-04, Vol.14 (4), p.490
• Main Authors: Haryuni, Ratna Dini, Nukui, Takamasa, Piao, Jin-Lan, Shirakura, Takashi, Matsui, Chieko, Sugimoto, Tomoyuki, Baba, Kousuke, Nakane, Shunya, Nakatsuji, Yuji
• Format: Article
• Language: English
• Subjects: Age; Aged; Antioxidants; Antioxidants - metabolism; Biomarkers - blood; Cardiovascular disease; Development and progression; Diabetes; Diagnosis; Dopamine receptors; Female; Health aspects; Humans; Hypertension; Ischemia; Kidney diseases; Male; Measurement; Metabolism; Middle Aged; Movement disorders; Neurodegenerative diseases; Neurological diseases; Oxidases; Oxidative Stress; Parkinson Disease - blood; Parkinson Disease - metabolism; Parkinson's disease; Pathogenesis; Pathophysiology; Patients; Reactive oxygen species; Reactive Oxygen Species - blood; Reactive Oxygen Species - metabolism; Statistical analysis; Substantia nigra; Thyroid diseases; Uric acid; Uric Acid - blood; Xanthine oxidase; Xanthine Oxidase - blood; Xanthine Oxidase - metabolism
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom14040490

Parkinson's disease (PD) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. The diagnosis of PD is sensitive since it shows clinical features that are common with other neurodegenerative diseases. In addition, most symptoms arise at the late stage of the disease, where most dopaminergic neurons are already damaged. Several studies reported that oxidative stress is a key modulator in the development of PD. This condition occurs due to excess reactive oxygen species (ROS) production in the cellular system and the incapability of antioxidants to neutralize it. In this study, we focused on the pathology of PD by measuring serum xanthine oxidase (XO) activity, which is an enzyme that generates ROS. Interestingly, the serum XO activity of patients with PD was markedly upregulated compared to patients with other neurological diseases (ONDs) as a control. Moreover, serum XO activity in patients with PD showed a significant correlation with the disease severity based on the Hoehn and Yahr (HY) stages. The investigation of antioxidant status also revealed that serum uric acid levels were significantly lower in the severe group (HY ≥ 3) than in the ONDs group. Together, these results suggest that XO activity may contribute to the development of PD and might potentially be a biomarker for determining disease severity in patients with PD.